Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Othman · SciRah

Researcher profile · Semantic Scholar

A. Othman

Share profile

A. Othman — researcher profile on SciRah

h-index: 35
Works: 126
Citations: 5,623

Most-cited papers

Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double‐Blind, Randomized Controlled Trial
R. Fleischmann, A. Pangan, I. Song, E. Mysler +8 more
2019Arthritis & Rheumatology415 citations
Semantic Scholar
Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial.
E. Guttman-Yassky, D. Thaçi, A. Pangan, C. Hong +9 more
2019Journal of Allergy and Clinical Immunology320 citations Open access
Semantic Scholar
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
J. Smolen, A. Pangan, P. Emery, W. Rigby +8 more
2019The Lancet312 citations
Semantic Scholar
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
G. Burmester, J. Kremer, F. E. Van den Bosch, A. Kivitz +6 more
2018The Lancet299 citations
Semantic Scholar
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
W. Sandborn, B. Feagan, E. Loftus, L. Peyrin-Biroulet +18 more
2020Gastroenterology287 citations Open access
Semantic Scholar
Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.
W. Sandborn, Subrata Ghosh, J. Panés, S. Schreiber +8 more
2020Gastroenterology234 citations Open access
Semantic Scholar
Efficacy and Safety of ABT‐494, a Selective JAK‐1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
M. Genovese, J. Smolen, M. Weinblatt, G. Burmester +7 more
2016Arthritis & Rheumatology192 citations Open access
Semantic Scholar
A Phase IIb Study of ABT‐494, a Selective JAK‐1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor Therapy
J. Kremer, P. Emery, H. Camp, A. Friedman +6 more
2016Arthritis & Rheumatology172 citations Open access
Semantic Scholar
Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
B. Feagan, J. Panés, M. Ferrante, A. Kaser +20 more
2018The Lancet Gastroenterology and Hepatology142 citations Open access
Semantic Scholar
Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia
E. Bain, L. Shafner, D. Walling, A. Othman +3 more
2017JMIR mHealth and uHealth131 citations Open access
Semantic Scholar
Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis
M. Mohamed, H. Camp, P. Jiang, R. Padley +2 more
2016Clinical Pharmacokinetics117 citations
Semantic Scholar
Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials
Ben Klünder, M. Mohamed, A. Othman
2017Clinical Pharmacokinetics76 citations Open access
Semantic Scholar
ABT‐122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin‐17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate
M. Genovese, M. Weinblatt, J. Aelion, H. Mansikka +7 more
2018Arthritis & Rheumatology73 citations Open access
Semantic Scholar
Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication
M. Mohamed, Ben Klünder, A. Othman
2019Clinical Pharmacokinetics72 citations Open access
Semantic Scholar
Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study
H. Kameda, T. Takeuchi, K. Yamaoka, M. Oribe +7 more
2020Rheumatology68 citations Open access
Semantic Scholar
Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high‐fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib
M. Mohamed, S. Jungerwirth, A. Asatryan, P. Jiang +1 more
2017British Journal of Clinical Pharmacology65 citations Open access
Semantic Scholar
Phase II Study of ABT‐122, a Tumor Necrosis Factor– and Interleukin‐17A–Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate
P. Mease, M. Genovese, M. Weinblatt, P. Peloso +7 more
2018Arthritis & Rheumatology59 citations Open access
Semantic Scholar
A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia.
G. Haig, E. Bain, W. Robieson, J. D. Baker +1 more
2016American Journal of Psychiatry58 citations Open access
Semantic Scholar
Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended‐Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials
M. Mohamed, J. Zeng, P. Marroum, I. Song +1 more
2018Clinical pharmacology in drug development57 citations Open access
Semantic Scholar
Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I–III Clinical Trials
Ben Klünder, R. Mittapalli, M. Mohamed, A. Friedel +2 more
2019Clinical Pharmacokinetics56 citations Open access
Semantic Scholar
Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure‐Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib
M. Mohamed, Denise Beck, H. Camp, A. Othman
2019Journal of clinical pharmacology52 citations Open access
Semantic Scholar
Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics
M. Mohamed, Sheryl Trueman, T. Feng, Jaclyn K. Anderson +2 more
2019Journal of clinical pharmacology47 citations Open access
Semantic Scholar
Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis
M. Genovese, M. Weinblatt, P. Mease, J. Aelion +8 more
2018Rheumatology44 citations
Semantic Scholar
ABT-126 monotherapy in mild-to-moderate Alzheimer’s dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension
L. Gault, R. Lenz, C. Ritchie, Andreas Meier +5 more
2016Alzheimer's Research & Therapy40 citations Open access
Semantic Scholar
The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study
G. Haig, Deli Wang, A. Othman, Jun Zhao
2016Neuropsychopharmacology39 citations Open access
Semantic Scholar
Development of In Vitro–In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation
M. Mohamed, Sheryl Trueman, A. Othman, Jian-Hwa Han +2 more
2019AAPS Journal38 citations Open access
Semantic Scholar
Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials
A. Nader, S. Stodtmann, A. Friedel, M. Mohamed +1 more
2019Journal of clinical pharmacology36 citations
Semantic Scholar
Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I–III Clinical Trials
A. Suleiman, M. Minocha, Amit Khatri, Yi-Nuo Pang +1 more
2019Clinical Pharmacokinetics36 citations Open access
Semantic Scholar
Safety, Tolerability, and Pharmacodynamics of ABT‐122, a Tumor Necrosis Factor– and Interleukin‐17–Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid Arthritis
R. Fleischmann, F. Wagner, A. Kivitz, H. Mansikka +7 more
2017Arthritis & Rheumatology35 citations Open access
Semantic Scholar
Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn’s Disease: Analyses of Phase I and II Trials
A. Suleiman, Amit Khatri, M. Minocha, A. Othman
2018Clinical Pharmacokinetics34 citations Open access
Semantic Scholar
Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa
A. Othman, M. Rosebraugh, K. Chatamra, C. Locke +1 more
2017Journal of Parkinson's Disease34 citations Open access
Semantic Scholar
Phase 1 first-in-human study of dalutrafusp alfa, an anti–CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors
A. Tolcher, Michael Gordon, K. Mahoney, A. Seto +9 more
2023Journal for ImmunoTherapy of Cancer33 citations Open access
Semantic Scholar
Phase 2 Study of ABT-122, a TNF- and IL-17A-Targeted Dual Variable Domain Immunoglobulin, in Psoriatic Arthritis With Inadequate Methotrexate Response.
P. Mease, M. Genovese, M. Weinblatt, P. Peloso +7 more
201833 citations
Semantic Scholar
Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis
Amit Khatri, D. Eckert, R. Oberoi, A. Suleiman +3 more
2019Journal of clinical pharmacology32 citations Open access
Semantic Scholar
Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Alicapistat, a Selective Inhibitor of Human Calpains 1 and 2 for the Treatment of Alzheimer Disease: An Overview of Phase 1 Studies
Hoi-Kei Lon, N. Mendonça, S. Goss, A. Othman +3 more
2018Clinical pharmacology in drug development32 citations
Semantic Scholar
Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
H. Florian, Andreas Meier, S. Gauthier, S. Lipschitz +5 more
2016Journal of Alzheimer's Disease32 citations
Semantic Scholar
Exposure–Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit–Risk Assessment in Rheumatoid Arthritis
A. Nader, M. Mohamed, I. Winzenborg, Eva Doelger +3 more
2019Clinical pharmacology and therapy29 citations Open access
Semantic Scholar
Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients
Yi-Nuo Pang, Amit Khatri, A. Suleiman, A. Othman
2019Clinical Pharmacokinetics28 citations Open access
Semantic Scholar
Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis
Amit Khatri, Ling Cheng, A. Camez, S. Ignatenko +2 more
2018Clinical Pharmacokinetics27 citations Open access
Semantic Scholar
Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics
Sheryl Trueman, M. Mohamed, T. Feng, A. Lacerda +2 more
2019Journal of clinical pharmacology25 citations Open access
Semantic Scholar
Therapeutic protein-drug interaction assessment for daclizumab high-yield process in patients with multiple sclerosis using a cocktail approach.
Jonathan Q. Tran, A. Othman, P. Wolstencroft, J. Elkins
2016British Journal of Clinical Pharmacology24 citations Open access
Semantic Scholar
Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety
A. Othman, K. Chatamra, M. Mohamed, S. Dutta +3 more
2015Clinical Pharmacokinetics24 citations Open access
Semantic Scholar
Exposure–Response Analyses for Upadacitinib Efficacy and Safety in the Crohn's Disease CELEST Study and Bridging to the Extended‐Release Formulation
M. Mohamed, Ben Klünder, A. Lacerda, A. Othman
2019Clinical pharmacology and therapy22 citations Open access
Semantic Scholar
Exposure–Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis
A. Suleiman, Amit Khatri, R. Oberoi, A. Othman
2019Clinical Pharmacokinetics22 citations
Semantic Scholar
Exposure–response analyses demonstrate no evidence of interleukin 17A contribution to efficacy of ABT-122 in rheumatoid or psoriatic arthritis
Amit Khatri, Ben Klünder, P. Peloso, A. Othman
2018Rheumatology22 citations
Semantic Scholar
Exposure–Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection
M. Mohamed, Ben Klünder, H. Camp, A. Othman
2019Clinical pharmacology and therapy21 citations Open access
Semantic Scholar
Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials
Amit Khatri, S. Goss, P. Jiang, H. Mansikka +1 more
2018Clinical Pharmacokinetics21 citations
Semantic Scholar
Meta‐Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority
H. Witjes, Amit Khatri, P. Diderichsen, J. Mandema +1 more
2019Clinical pharmacology and therapy20 citations Open access
Semantic Scholar
Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail
M. Mohamed, T. Feng, J. Enejosa, O. Fisniku +1 more
2019Journal of clinical pharmacology20 citations Open access
Semantic Scholar
Exposure–Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients
Amit Khatri, A. Suleiman, Akshanth R. Polepally, A. Othman
2019Clinical pharmacology and therapy19 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Mohamed×18
Invite
M. Mohamed — researcher profile on SciRah
Amit Khatri×15
Invite
Amit Khatri — researcher profile on SciRah
A. Pangan×9
Invite
A. Pangan — researcher profile on SciRah
H. Camp×7
Invite
H. Camp — researcher profile on SciRah

×6

Invite

Yihan Li — researcher profile on SciRah

Invite

M. Genovese — researcher profile on SciRah

Ben Klünder×6

Invite

Ben Klünder — researcher profile on SciRah

Invite

H. Mansikka — researcher profile on SciRah

Invite

A. Suleiman — researcher profile on SciRah

M. Weinblatt×5

Invite

M. Weinblatt — researcher profile on SciRah

Invite

P. Peloso — researcher profile on SciRah

Invite

N. Khan — researcher profile on SciRah